🔍 Is #axSpA overdiagnosed locally? IMPROVE-axSpA prosp study (n=969): Yes! Only 54% locally confirmed centrally #OP0105 #EULAR2026 @RheumNow https://t.co/VqCPbbCHLB

• https://x.com/Nellziade/status/2062241054779195511/photo/1

💉 IXE+TZP beat IXE alone in obese PsA? YES - TOGETHER-PsA RCT 33.5% vs 20.4% ACR50 at week 36 in 271 patients OP069 #EULAR2026 @RheumNow @DrLauraCoates @AlexisOgdie https://t.co/orvAe38alc

• https://x.com/Nellziade/status/2062241947532546238/photo/1

The first two days of EULAR 2026 have delivered a flood of new data, late-breaking science, and clinical insights. Don't spend hours sorting through hundreds of abstracts; RheumNow will do it for you. Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty as they break down the https://t.co/eAPV6h5FAn

• Home | RheumNow

🔍 What defines a positive MRI for #axSpA? SPARTAN-SSR consensus (n=1,050): BME≥3 slices or 2/3 lesions in ≥3 SIJ quadrants #OP0100 #EULAR2026 @RheumNow https://t.co/nfhzGxBZOm

• https://x.com/Nellziade/status/2062239875663908892/photo/1

#OP091 at #EULAR2026: RA was associated with a 44% higher risk of ischaemic stroke versus the general population, with higher stroke-related mortality and disability. Encouragingly, excess stroke risk was no longer significant in more recent RA cohorts. @RheumNow

#OP090 at #EULAR2026: In this nationwide Danish study, RA patients with lung cancer had similar survival outcomes to patients without RA. Importantly, immune checkpoint inhibitor treatment did not appear to worsen outcomes in patients with pre-existing RA. @RheumNow

22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026

This retrospective cohort of NPSLE pts showed clinical assocs with MRI findings: Pts w/ focal symptoms - abn MRI Pts w/ diffuse symptoms - normal MRI except brain atrophy Interesting to know how this can aid in future mgt strategies for NPSLE OP093 @RheumNow #EULAR2026 https://t.co/omvdWk6EZK

• https://x.com/RHEUMarampa/status/2062205949989835024/photo/1

Kicking off Clinical Abstracts: Comorbidities in RA session at #EULAR2026 with #OP084 ANCHOR-RA found 9.1% at-risk RA patients had previous undiagnosed ILD on screening HRCT. Older age, smoking, male sex & ⬆️DAS28 linked to RA-ILD. Important data for earlier detection @RheumNow

Does #Rx w #immunesuppression w #antifibrotic Help #SARD-ILD? YES. N=40 SARD-ILD, 1/2 w UIP pattern Use of #IS w #antifibrotic pt group had better survival Small N and ?channeling bias But interesting results TAke home : Use IS + antifibrotic #EULAR2026 #POS0530 @RheumNow https://t.co/tfxVVw27jJ

• https://x.com/Janetbirdope/status/2062186222794023284/photo/1

Not all "difficult-to-treat" #PsA definitions are equal. Real-world DEPAR cohort (n=885): 20% met GRAPPA complex-to-manage vs only 4% EULAR difficult-to-manage criteria. Definition choice determines who gets identified, and who gets left behind. @RheumNow #EULAR2026 POS0446

#EULAR2026 POS0440 1-Year Open Label Extension Study of 6-monthly Inebilizumab, a CD19 depleter in #IgG4 disease: -No flare in INEB group; 6% flare in PBO-INEB -10.9% serious infections -1 pt discontinued due to low IgG Interested to see longer-term safety data @RheumNow https://t.co/PPUw81T8DZ

• https://x.com/Yuz6Yusof/status/2062175613658550729/photo/1

Prof. Pedro Machado shares this important slide on a quick guide to #vaccination in patients w/ RMDs highlighting which vaccines are universally indicated, accdg to epidemiologic risk and w/ CIs. #EULAR2026 @RheumNow https://t.co/JmTSC1uaph

• https://x.com/RHEUMarampa/status/2062165971884752917/photo/1

#EULAR2026 General Assembly is ON! Record-breaking 5'705 abstracts from 102 countries 187 scientific sessions ahead @rheumnow https://t.co/0kAqND11L7

• https://x.com/Nellziade/status/2062112004593078356/photo/1